Sunday, November 23, 2014

Cipher to begin trading on NASDAQ on Monday

Cipher to begin trading on NASDAQ on Monday

November 21, 2014 by · Leave a Comment 

Tweet Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND) has been approved for listing and trading on the NASDAQ Global Market, effective at the open on Monday, under the ticker symbol CPHR. The common shares will continue to be listed on the Toronto Stock Exchange, however, the company’s ticker symbol will change to CPH also on Monday. “Listing on […]

Tandem Diabetes in data partnership with Tidepool

Tandem Diabetes in data partnership with Tidepool

November 21, 2014 by · Leave a Comment 

Tweet Tandem Diabetes Care (NASDAQ:TNDM) has entered into a partnership with Tidepool, a non-profit dedicated to improving diabetes therapy management by offering an open source software platform that increases diabetes data accessibility. The accord will enable users of the Tidepool Platform, which is currently under development, to download and access data from Tandem’s t:slim Insulin […]

Amarantus completes enrollment in expanded LP-002 study

Amarantus completes enrollment in expanded LP-002 study

November 20, 2014 by · Leave a Comment 

Tweet Amarantus Bioscience Holdings (OTCQB:AMBS) has completed enrollment in the expanded LP-002 study of the Lymphocyte Proliferation (LymPro Test) blood diagnostic for Alzheimer’s disease (AD). The test assesses LymPro’s predictive value in mild, moderate and severe AD vs. healthy controls. Amarantus expects to announce the full results of its in-depth analysis of the full mild-to-severe […]

Transition posts encouraging study results in Down syndrome

Transition posts encouraging study results in Down syndrome

November 20, 2014 by · Leave a Comment 

Tweet Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) has announced encouraging results of a clinical study of neuropsychiatric drug candidate, ELND005, in young adults with Down syndrome. Transition’s wholly owned subsidiary, Transition Therapeutics Ireland (TTIL), completed this first study in Down syndrome subjects without dementia to allow optimal dose selection for future larger studies. The study enrolled 23 […]

Vital Therapies names John Dunn as general counsel

Vital Therapies names John Dunn as general counsel

November 20, 2014 by · Leave a Comment 

Tweet Vital Therapies (NASDAQ:VTL) has appointed John Dunn as general counsel, reporting to Terry Winters, CEO and co-chairman. Mr. Dunn joins the company with over 30 years of corporate and legal experience. Most recently, Mr. Dunn provided legal and corporate development advisory services to technology and life sciences companies. From 2004 to 2012, he was […]

Highline starts Mast Therapeutics at buy

Highline starts Mast Therapeutics at buy

November 19, 2014 by · Leave a Comment 

Tweet Highline Research Advisors has initiated coverage of Mast Therapeutics (NASDAQ:MSTX) with a “buy” rating and price target of $3. The stock closed at 48 cents on Tuesday. Mast is a development-stage, small cap biotech developing a novel poloxamer (MST-188) in acute ischemic conditions. Analyst Michael Higgins writes that Mast’s lead program (EPIC) is a […]

Cynapsus posts positive top-line PD results

Cynapsus posts positive top-line PD results

November 19, 2014 by · Leave a Comment 

Tweet Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH) has released positive top-line results from its CTH-105 Phase 2 clinical trial of APL-130277 for the management of OFF motor symptoms of Parkinson’s disease (PD), which leave patients rigid and unable to move and communicate. Out of 16 patients treated with APL-130277, a fast-acting, sublingual, thin filmstrip formulation of apomorphine, […]

Knight sells priority review voucher for $125-million

Knight sells priority review voucher for $125-million

November 19, 2014 by · Leave a Comment 

Tweet Knight Therapeutics (TSX:GUD) has sold its neglected tropical disease priority review voucher (PRV) to Gilead Sciences for $125-million. “We are thrilled to successfully transfer our priority review voucher in expectation that this will encourage others to invest in R&D for neglected tropical diseases for the benefit of humanity,” Jonathan Goodman, president and CEO of […]

HCW starts Can-Fite BioPharma at buy

HCW starts Can-Fite BioPharma at buy

November 18, 2014 by · Leave a Comment 

Tweet H.C. Wainwright has initiated coverage of Can-Fite BioPharma (NYSE:CANF) with a “buy” recommendation and 12-month target price of $7, based on a risk-adjusted revenues and earnings per share multiples valuation methodology. The stock closed at $2.43 on Monday. Analyst Reni Benjamin writes that Can-Fite’s biotechnology franchise is focused on small molecule modulators of the […]

HCW starts Aldeyra Therapeutics at buy

HCW starts Aldeyra Therapeutics at buy

November 18, 2014 by · Leave a Comment 

Tweet H.C. Wainwright has launched coverage of Aldeyra Therapeutics (NASDAQ:ALDX) with a “buy” rating and a price target of $13. The stock closed at $7.65 on Monday. Analyst Swayampakula Ramakanth writes that Aldeyra is embarking on a strategy to develop a therapy to trap free aldehydes, which have a high propensity to bind to macromolecules, […]

Next Page »

Email Newsletters with Constant Contact
Google+